Company intelligence / Profile preview
Xiangxue Precision Medical Technology
Guangzhou, Guangdong, Chinaxlifesc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TAEST16001 (NY-ESO-1 TCR-T therapy) has reached Phase 2 for soft tissue sarcoma and advanced clinical pipelines[1][8]. Early clinical studies in China have shown safety and efficacy signals for TCR-T cell therapy platforms[7].
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyCell therapyLentivirus (GMP-grade, for vector delivery)[1][2]
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Axis Therapeutics Limited (joint preclinical program: TCRT ESO A2)[1]Xiangxue Pharmaceutical (collaborative relationship; possible shared R&D)[1][8]GE Healthcare (manufacturing platform/technology partnership)[5]
Beyond the preview
Go deeper on Xiangxue Precision Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiangxue Precision Medical Technology.